Argent BioPharma Limited

ASX:MXCDA Stock Report

Market Cap: AU$2.5m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MGC Pharmaceuticals Management

Management criteria checks 4/4

MGC Pharmaceuticals' CEO is Roby Zomer, appointed in Feb 2016, has a tenure of 7.75 years. total yearly compensation is A$354.02K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.76% of the company’s shares, worth A$18.77K. The average tenure of the management team and the board of directors is 2.8 years and 6.3 years respectively.

Key information

Roby Zomer

Chief executive officer

AU$354.0k

Total compensation

CEO salary percentage100.0%
CEO tenure7.8yrs
CEO ownership0.8%
Management average tenure2.8yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Roby Zomer's remuneration changed compared to MGC Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023AU$354kAU$354k

-AU$21m

Mar 31 2023n/an/a

-AU$22m

Dec 31 2022n/an/a

-AU$23m

Sep 30 2022n/an/a

-AU$22m

Jun 30 2022AU$629kAU$422k

-AU$20m

Mar 31 2022n/an/a

-AU$19m

Dec 31 2021n/an/a

-AU$18m

Sep 30 2021n/an/a

-AU$17m

Jun 30 2021AU$481kAU$281k

-AU$16m

Dec 31 2020n/an/a

-AU$13m

Sep 30 2020n/an/a

-AU$16m

Jun 30 2020AU$440kAU$290k

-AU$19m

Dec 31 2019n/an/a

-AU$18m

Sep 30 2019n/an/a

-AU$14m

Jun 30 2019AU$495kAU$330k

-AU$11m

Dec 31 2018n/an/a

-AU$7m

Sep 30 2018n/an/a

-AU$7m

Jun 30 2018AU$498kAU$334k

-AU$8m

Mar 31 2018n/an/a

-AU$10m

Dec 31 2017n/an/a

-AU$12m

Sep 30 2017n/an/a

-AU$10m

Jun 30 2017AU$783kAU$233k

-AU$8m

Compensation vs Market: Roby's total compensation ($USD227.27K) is about average for companies of similar size in the Australian market ($USD295.83K).

Compensation vs Earnings: Roby's compensation has been consistent with company performance over the past year.

CEO

Roby Zomer (43 yo)

7.8yrs

Tenure

AU$354,018

Compensation

Mr. Roby Reuven Zomer is a Co-Founder of MGC Pharmaceuticals Limited and served as its Interim Chief Financial Officer since April 2022 until April 2022. Mr. Zomer has been Managing Director since May 2018...

Leadership Team

NamePositionTenureCompensationOwnership
Roby Zomer
Co-Founder7.8yrsAU$354.02k0.76%
A$ 18.8k
Tom Cairns
Chief Accounting Officerless than a yearno datano data
Yifat Steuer
Deputy CEO & COO1.1yrsno data0.39%
A$ 9.5k
Nicole Godresse
Global Chief Sales Officer2.8yrsno datano data
Amir Polak
Chief Pharmaceutical Development Officerno datano datano data
Sabina Suljakovic
Head of the Quality Assurance Department3.2yrsno datano data
Nadya Lisovoder
Chief Medical Officerno datano datano data
Sasha Friedman
Deputy CEOno datano datano data
Yair Tal
Chief Information Security Officerno datano datano data
Robert Clements
Chief Commercial Officer1.3yrsno datano data
Itay Nissim
Chief Manufacturing & Supply Chain Officerno datano datano data
Hugh Winters
Chief Executive Officer of MGC Derma5yrsno datano data

2.8yrs

Average Tenure

Experienced Management: MXCDA's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Roby Zomer
Co-Founder7.8yrsAU$354.02k0.76%
A$ 18.8k
Stephen Parker
Non-Executive Chairman & Senior Independent Director4.7yrsAU$30.59k0.045%
A$ 1.1k
Ross Grant Walker
Chairman of Strategic Advisory Board & Independent Non-Executive Director7.8yrsAU$44.00k0.11%
A$ 2.8k
Uri Kramer
Member of Strategic Advisory Board7.3yrsno datano data
Layton Mills
Independent Non-Executive Directorless than a yearno datano data
Wendyl D'Souza
Member of Medical Advisory Board5.3yrsno datano data

6.3yrs

Average Tenure

Experienced Board: MXCDA's board of directors are considered experienced (6.3 years average tenure).